Everything Your Heart Desires
Know Where You Stand:
Varicose Veins Are a Sign of an 
Underlying Medical Problem.

Clinical Research Studies

Since 1997, Cardiology Associates of North MS has been a leader in advancing medical science through clinical research. With a dedicated research department of 9 employees, our cardiologists are investigating new approaches to preventing and treating cardiovascular conditions and diseases. It is through research that medical breakthroughs and better treatment modalities are established. Our clinical research program allows us to make available promising new drug therapies and devices to our patients. Not only does involvement in these studies keep our staff abreast of the latest treatment, but research protocols often provide medication and services to our patients that are not yet available to the general population. We encourage you to consider a research study when appropriate.


Cardiology Associates of North MS First in the Nation!!!

Earlier this year, cardiologist Dr. Barry Bertolet and his team implanted the nation's first bioresorbable vascular scaffold (BVS) as part of a research study at North MS Medical Center. ABSORB, the world's first drug-eluting BVS, works by restoring blood flow to the heart similar to a metal stent, but then dissolves into the body. The result is a treated vessel that may resume a more natural function and movement because it is free of a permanent metal stent. The device is referred to as a scaffold because it is a temporary structure, unlike a stent, which is a permanent implant. The scaffold supports the vessel until the artery can stay open on its own, and then dissolves naturally. "This technology represents a true shift in the way doctors will treat patients with severe obstructive coronary artery disease," Bertolet says. "We are excited about ABSORB because it may expand long-term diagnostic and treatment optio ns for cardiac patients."

Mississippi's First Vagal Nerve Stimulator for Heart Failure Implanted in Tupelo, MS

Cardiology Associates of North MS physician, Dr. Karl Crossen, and neurosurgeon Dr. Louis Rosa, teamed up to implant the state's first vagal nerve stimulator as part of a clinical research study to treat heart failure through nerve stimulation in the neck. Research demonstrates a connection between the heart and the brain that could benefit heart failure patients. Since 1997, vagal nerve stimulation has been used to control seizures in epilepsy patients and more recently to treat clinical depression. This clinical trial is the first time vagal nerve stimulation is being used to treat heart failure. Like a traditional pacemaker, the CardioFit device is implanted under the skin of the chest and attached to the heart--but it is also connected to a nerve in the neck. The device sends electrical pulses to the nerve, which sends signals to the heart. Most patients are treated with prescription drugs that man age some symptoms, but these medications can't stop deterioration caused by heart failure. The clinical trial will assess whether combining treatment with the CardioFit nerve stimulator and drug therapy is more effective than prescription drug therapy alone.




[PRESS RELEASE]
Cardiologist Receives FDA Approval for HOCM Treatment

Hypertrophic Obstructive Cardiomyopathy, or HOCM, is a genetic disease in which the septum of the heart is enlarged or thickened. This thickening causes such symptoms as shortness of breath, chest pain, fainting, congestive heart failure, and an abnormal heart beat that can lead to sudden cardiac death. Current treatment to decrease the thickening of the septum in either to surgically remove part of the septum (open heart surgery) or to inject alcohol into a blood vessel to 'kill' part of the septum. The only proven treatment for sudden cardiac death is the implantation of an ICD, or Implantable Cardiac Defibrillator. Cardiology Associates physician, Dr. Karl Crossen, teamed up with Research Manager, Marsha Jones, RN, BSN, CCRP, to write a research protocol for radio-frequency septal ablation, a novel technique in which Dr. Crossen uses radio-frequency to ablate or 'burn' areas of the septum. The procedure does not require invasive surgery or injecting alcohol into blood vessels. After 2 years of working with the FDA (Food and Drug Administration) and the North MS Medical Center, Dr. Crossen and Ms. Jones were granted approval to conduct the research study on 10 patients. On December 12, 2012, Mr. Eugene Ward was the first pt. to have the procedure performed through the research study.

 

Cardiology Associates of North MS First in the Nation YET AGAIN!!!

On August 24, 2016, electrophysiologist Dr. Jim Stone along with the Cardiology Associates Research team became the first in the nation to implant a new device as part of a global clinical trial. The AMULET device is an investigational device manufactured by St Jude Medical to study whether or not the device will reduce the risk of stroke in patients with atrial fibrillation.  The device blocks the small, left atrial appendage in the heart where blood clots can form because of the heart beating in the irregular rhythm, atrial fibrillation.  Sealing the left atrial appendage with a device, like the AMULET, allows patients to stop taking blood thinning medications, such as Coumadin, Eliquis, and Xarelto. 


 

 

[PRESS RELEASES]
WHAT’S NEW AT
NMMC HEART INSTITUTE

NMMC IMPLANTS NATION'S FIRST
BIORESORBABLE HEART DEVICE

TUPELO MAN GETS
THE SHOCK OF HIS LIFE

 


CANM cardiologists are currently engaged in a diverse assortment of clinical studies investigating new approaches to preventing and treating cardiovascular conditions and diseases. As a result, we are able to offer innovative treatment options and the very latest therapies to our patients. For more information regarding our clinical trials, Click Here.